Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DOJG79
|
|||
| Drug Name |
SEL120
|
|||
| Synonyms |
SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1 | [1] | |
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1 | [1] | ||
| Company |
Ryvu Therapeutics
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C15H19Br2ClN4
|
|||
| Canonical SMILES |
CC1=C2C3=C(CCCN3C(=N2)N4CCNCC4)C(=C1Br)Br.Cl
|
|||
| InChI |
1S/C15H18Br2N4.ClH/c1-9-11(16)12(17)10-3-2-6-21-14(10)13(9)19-15(21)20-7-4-18-5-8-20;/h18H,2-8H2,1H3;1H
|
|||
| InChIKey |
GQXLWUCQESKBSC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1609452-30-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cyclin-dependent kinase 19 (CDK19) | Target Info | Inhibitor | [2] |
| Cyclin-dependent kinase 8 (CDK8) | Target Info | Inhibitor | [2] | |
| Reactome | PPARA activates gene expression | |||
| NOTCH1 Intracellular Domain Regulates Transcription | ||||
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | ||||
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | ||||
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | ||||
| Transcriptional regulation of white adipocyte differentiation | ||||
| WikiPathways | Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | ||||
| Transcriptional Regulation of White Adipocyte Differentiation | ||||
| Signaling by NOTCH1 | ||||
| SREBP signalling | ||||
| Generic Transcription Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04021368) SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Ryvu Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.